BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals logoBioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BCRX
  • CUSIP: 09058V10
Key Metrics:
  • Previous Close: $4.42
  • 50 Day Moving Average: $4.462
  • 200 Day Moving Average: $3.465
  • 52-Week Range: $1.63 - $12.88
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.64
  • P/E Growth: -0.230
  • Market Cap: $325.39M
  • Outstanding Shares: 73,700,000
  • Beta: 3.19
  • Net Margins: -285.24%
  • Return on Equity: -187.98%
  • Return on Assets: -64.08%
  • Debt-to-Equity Ratio: 0.19%
  • Current Ratio: 0.82%
  • Quick Ratio: 0.79%
Additional Links:
Companies Related to BioCryst Pharmaceuticals:

Analyst Ratings

Consensus Ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) (?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.36)
Consensus Price Target: $8.22 (86.44% upside)

Analysts' Ratings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateFirmActionRatingPrice TargetDetails
9/8/2016FBR & CoReiterated RatingBuyView Rating Details
8/12/2016Piper Jaffray Cos.UpgradeNeutral -> Overweight$5.00 -> $8.00View Rating Details
8/5/2016HC WainwrightReiterated RatingBuyView Rating Details
8/5/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details
8/5/2016Jefferies GroupBoost Price TargetHold$2.00 -> $3.00View Rating Details
8/4/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
2/26/2016Noble FinancialReiterated RatingBuy$8.00View Rating Details
2/9/2016Rodman & RenshawLower Price TargetBuy$24.00 -> $10.00View Rating Details
2/8/2016Needham & Company LLCDowngradeBuy -> HoldView Rating Details
11/11/2015Bank of America Corp.DowngradeNeutral -> Underperform$12.00 -> $10.00View Rating Details
11/10/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details
8/10/2015MLV & Co.Reiterated RatingBuy$15.00View Rating Details
(Data available from 9/30/2014 forward)


Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.26)($0.22)$3.92 million$4.80 millionViewN/AView Earnings Details
5/5/2016Q116($0.23)($0.31)$5.42 million$4.82 millionViewN/AView Earnings Details
2/23/2016Q415($0.26)($0.25)$6.34 million$4.60 millionViewListenView Earnings Details
11/5/2015Q315($0.20)($0.20)$6.77 million$11.00 millionViewListenView Earnings Details
8/7/2015Q215($0.22)$0.06$7.10 million$25.80 millionViewListenView Earnings Details
5/8/2015Q115($0.24)($0.21)$4.30 million$6.80 millionViewListenView Earnings Details
2/18/2015Q414($0.21)($0.16)$3.64 million$5.40 millionViewListenView Earnings Details
11/6/2014Q314($0.20)($0.12)$2.11 million$3.20 millionViewListenView Earnings Details
8/5/2014Q214($0.19)($0.23)$2.32 million$1.50 millionViewN/AView Earnings Details
5/8/2014Q114($0.17)($0.17)$3.34 million$3.50 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.09)$8.81 million$10.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.14)($0.14)$2.01 million$2.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.14)($0.23)$2.01 million$0.82 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.15)($0.09)$1.31 million$3.60 millionViewN/AView Earnings Details
2/19/2013Q4 2012($0.16)($0.22)$4.02 million$4.10 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.19)$4.63 million$5.80 millionViewN/AView Earnings Details
8/2/2012($0.26)($0.25)ViewN/AView Earnings Details
5/7/2012($0.26)($0.13)ViewN/AView Earnings Details
2/16/2012($0.33)($0.29)ViewN/AView Earnings Details
11/2/2011($0.30)($0.32)ViewN/AView Earnings Details
8/4/2011($0.26)($0.36)ViewN/AView Earnings Details
5/4/2011($0.20)($0.29)ViewN/AView Earnings Details
2/10/2011($0.21)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Current Year EPS Consensus Estimate: $-1.03 EPS
Next Year EPS Consensus Estimate: $-0.95 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.24)($0.20)($0.23)
Q2 20165($0.25)($0.17)($0.22)
Q3 20163($0.26)($0.22)($0.24)
Q4 20163($0.26)($0.24)($0.25)
(Data provided by Zacks Investment Research)


Dividend History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 70.34%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2016Alane P BarnesVPSell8,357$4.27$35,684.39View SEC Filing  
8/25/2016Yarlagadda S BabuVPSell30,000$4.06$121,800.00View SEC Filing  
8/16/2016Bros. Advisors Lp BakerMajor ShareholderSell4,046,590$5.00$20,232,950.00View SEC Filing  
8/12/2016Thomas R Staab IIInsiderSell5,864$5.18$30,375.52View SEC Filing  
8/9/2016Thomas R Staab IIInsiderSell14,577$4.43$64,576.11View SEC Filing  
1/28/2016Bros. Advisors Lp Bakermajor shareholderBuy88,345$6.95$613,997.75View SEC Filing  
1/22/2016Bros. Advisors Lp Bakermajor shareholderBuy106,800$7.28$777,504.00View SEC Filing  
1/20/2016Bros. Advisors Lp Bakermajor shareholderBuy52,695$6.87$362,014.65View SEC Filing  
1/19/2016Bros. Advisors Lp Bakermajor shareholderBuy92,200$7.12$656,464.00View SEC Filing  
1/15/2016Bros. Advisors Lp Bakermajor shareholderBuy200,000$7.46$1,492,000.00View SEC Filing  
12/21/2015Thomas R Staab IICFOSell3,052$10.86$33,144.72View SEC Filing  
12/17/2015Thomas R Staab IICFOSell3,000$10.49$31,470.00View SEC Filing  
7/20/2015Thomas R Staab IICFOSell3,500$16.50$57,750.00View SEC Filing  
6/22/2015Thomas R Staab IICFOSell3,750$16.00$60,000.00View SEC Filing  
6/19/2015Alane P BarnesVPSell3,000$15.00$45,000.00View SEC Filing  
6/19/2015Jon P StonehouseCEOSell20,000$15.02$300,400.00View SEC Filing  
6/19/2015Thomas R Staab IICFOSell16,375$14.36$235,145.00View SEC Filing  
6/19/2015William P SheridanCMOSell70,389$15.05$1,059,354.45View SEC Filing  
6/5/2015Thomas R Staab IICFOSell6,000$12.75$76,500.00View SEC Filing  
5/18/2015Thomas R Staab IICFOSell3,000$11.00$33,000.00View SEC Filing  
3/19/2015Yarlagadda S BabuVPSell12,105$10.16$122,986.80View SEC Filing  
3/5/2015Yarlagadda S BabuVPSell37,400$10.59$396,066.00View SEC Filing  
3/4/2015Yarlagadda S BabuVPSell10,495$10.50$110,197.50View SEC Filing  
2/20/2015Nancy J HutsonDirectorBuy10,000$10.27$102,700.00View SEC Filing  
12/30/2014William P SheridanCMOSell128,399$12.36$1,587,011.64View SEC Filing  
12/29/2014Thomas R Staab IICFOSell9,500$12.56$119,320.00View SEC Filing  
12/29/2014William P SheridanCMOSell105,295$12.43$1,308,816.85View SEC Filing  
8/27/2014Thomas R Staab IICFOSell10,000$13.58$135,800.00View SEC Filing  
7/1/2014Thomas R Staab IICFOSell3,125$13.00$40,625.00View SEC Filing  
6/23/2014Thomas R Staab IICFOSell3,125$12.49$39,031.25View SEC Filing  
6/17/2014Thomas R Staab IICFOSell3,125$12.00$37,500.00View SEC Filing  
3/14/2014Thomas Staab IICFOSell3,125$11.24$35,125.00View SEC Filing  
3/6/2014Kenneth Lee, Jr.DirectorSell12,665$12.69$160,718.85View SEC Filing  
11/12/2013George AbercrombieDirectorBuy3,000$6.19$18,570.00View SEC Filing  
8/1/2013Felix BakerMajor ShareholderBuy1,136,364$4.40$5,000,001.60View SEC Filing  
3/5/2013George B AbercrombieDirectorBuy3,000$1.23$3,690.00View SEC Filing  
12/14/2012Peder JensenDirectorBuy20,000$1.51$30,200.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for BioCryst Pharmaceuticals (NASDAQ:BCRX)
News IconLatest Analyst Ratings For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - The De Soto Edge (NASDAQ:BCRX) - September 29 at 4:00 PM logoBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Post EPS Of $-0.22 - (NASDAQ:BCRX) - September 29 at 4:00 PM logoBioCryst Closes $23 Million Senior Credit Facility (NASDAQ:BCRX) - September 29 at 8:52 AM logoBIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin (NASDAQ:BCRX) - September 29 at 8:52 AM
News IconBiotech news that matter for investors: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Celldex Therapeutics, Inc ... - The Voice Registrar (NASDAQ:BCRX) - September 26 at 3:52 PM logoBioCryst Pharmaceuticals : Closes $23 Million Senior Credit Facility (NASDAQ:BCRX) - September 26 at 8:31 AM logoETF’s with exposure to BioCryst Pharmaceuticals, Inc. : September 21, 2016 (NASDAQ:BCRX) - September 21 at 4:40 PM
News IconNews review of 2 biotech stocks: BioCryst Pharmaceuticals (NASDAQ:BCRX), Vanda Pharmaceuticals (NASDAQ:VNDA) - The Voice Registrar (NASDAQ:BCRX) - September 20 at 5:55 PM
News IconBiotech Stocks Worth a Closer Look: Sangamo Biosciences Inc. (NASDAQ:SGMO), BioCryst Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:BCRX) - September 20 at 5:55 PM
News IconQuarterly EPS analysis of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Newburgh Press (NASDAQ:BCRX) - September 20 at 5:55 PM
News IconWhat are Brokerage Firms Saying About BioCryst Pharmaceuticals ... - Frisco Fastball (NASDAQ:BCRX) - September 17 at 3:46 PM
News IconStock Perspective: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Earnings in View - Frisco Fastball (NASDAQ:BCRX) - September 15 at 4:18 PM
News IconTime To Put On The Watch List? - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Sangamo Biosciences Inc ... - The Voice Registrar (NASDAQ:BCRX) - September 15 at 4:18 PM
News IconHealthcare Shares Need To Consider: BioCryst Pharmaceuticals ... - National Daily Press (NASDAQ:BCRX) - September 14 at 3:48 PM
News IconTime To Put On The Watch List? - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Inovio Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:BCRX) - September 13 at 4:47 PM
News IconTime To Put On The Watch List? - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Rock Creek Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:BCRX) - September 9 at 3:43 PM logoBioCryst Pharma (BCRX) Offers Positive Results from BCX4430 PoC Study in Ebola Virus - (NASDAQ:BCRX) - September 9 at 8:38 AM
News IconBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) From The Analysts Point of View - National Daily Press (NASDAQ:BCRX) - September 9 at 8:38 AM
News IconActive Eye Catching Stocks- BioCryst Pharmaceuticals (BCRX), Retrophin (RTRX), Immune Pharmaceuticals (IMNP) - Seneca Globe (NASDAQ:BCRX) - September 8 at 8:54 AM
News IconStock Showing Gains in Today's Session: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Post News (NASDAQ:BCRX) - September 7 at 3:45 PM logoBioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model (NASDAQ:BCRX) - September 7 at 11:01 AM logoBioCryst to Present at the Baird 2016 Global Healthcare Conference September 8 (NASDAQ:BCRX) - August 31 at 3:46 PM
News IconBioCryst Pharmaceuticals Inc (NASDAQ:BCRX): A Play On The Zika Virus (NASDAQ:BCRX) - August 30 at 9:10 AM logoETF’s with exposure to BioCryst Pharmaceuticals, Inc. : August 29, 2016 (NASDAQ:BCRX) - August 29 at 4:21 PM logoResearch Reports Initiation on Biotech Stocks -- Hemispherx Biopharma, Vascular Biogenics, BioCryst Pharma, and Alnylam Pharma (NASDAQ:BCRX) - August 29 at 8:34 AM logoAfter Yesterday's Decline of 5.13%, BioCryst Pharmaceuticals Offers Investors Better Value (NASDAQ:BCRX) - August 25 at 9:10 PM
News IconBiotech news that matter for investors: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Arrowhead Pharmaceuticals ... - The Voice Registrar (NASDAQ:BCRX) - August 24 at 12:00 PM logoBiocryst Pharmaceuticals Inc (BCRX): Billionaire David E. Shaw’s Fund Increases Stake (NASDAQ:BCRX) - August 23 at 3:50 PM logoBIOCRYST PHARMACEUTICALS INC Financials (NASDAQ:BCRX) - August 17 at 3:52 PM logoBiocryst Pharmaceuticals Inc (BCRX): Baker Bros. Advisors Unloads Nearly 4 Million Shares (NASDAQ:BCRX) - August 17 at 11:57 AM
News Icon2 Biotech Stocks News And Price Trends: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), ZIOPHARM Oncology, Inc ... - The Voice Registrar (NASDAQ:BCRX) - August 16 at 3:51 PM logoWill BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hit $10 Price Target? - Investor Newswire (NASDAQ:BCRX) - August 16 at 12:28 PM
News IconStocks to Watch: BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX), First Solar, Inc.(NASDAQ:FSLR) - NYSE Journal (press release) (NASDAQ:BCRX) - August 15 at 3:53 PM logoETF’s with exposure to BioCryst Pharmaceuticals, Inc. : August 15, 2016 (NASDAQ:BCRX) - August 15 at 11:00 AM logoBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Brokerage Rating Update - Investor Newswire (NASDAQ:BCRX) - August 12 at 3:58 PM logoBioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:BCRX) - August 12 at 3:58 PM logoBioCryst Pharma (BCRX) Does First Patient in BCX7353 APeX-1 Study (NASDAQ:BCRX) - August 12 at 12:25 PM logoBioCryst Pharma upgraded by Piper Jaffray (NASDAQ:BCRX) - August 12 at 12:25 PM
News IconAnalyst's keeping an Eye on: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Post Registrar (NASDAQ:BCRX) - August 11 at 9:40 PM logo10:19 am BioCryst Pharma doses the first subject in the APeX-1 clinical trial of BCX7353 for the oral treatment of hereditary angioedema (NASDAQ:BCRX) - August 11 at 12:32 PM logoBIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:BCRX) - August 11 at 12:32 PM logoBioCryst Announces Initiation of the APeX-1 Clinical Trial of BCX7353 for Hereditary Angioedema (NASDAQ:BCRX) - August 11 at 12:32 PM logoHere's the Buzz Behind BioCryst Pharmaceuticals, Inc.'s 27% Gain in July (NASDAQ:BCRX) - August 11 at 12:32 PM logoBulls pile into Biocryst Pharmaceuticals (NASDAQ:BCRX) - August 10 at 4:11 PM logoBiocryst Where To From Here? - Seeking Alpha (NASDAQ:BCRX) - August 10 at 7:52 AM logoStocks inside Analysts Limelight: Amarin Corporation PLC (NASDAQ:AMRN) , BioCryst Pharmaceuticals, Inc ... - Street Updates (NASDAQ:BCRX) - August 10 at 7:52 AM
News IconBiggest Movers in Healthcare: MannKind Corp. (NASDAQ:MNKD), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - TWN (NASDAQ:BCRX) - August 10 at 7:52 AM logoBIOCRYST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:BCRX) - August 8 at 3:49 PM logoEdited Transcript of BCRX earnings conference call or presentation 4-Aug-16 3:00pm GMT (NASDAQ:BCRX) - August 5 at 9:09 PM logoNotable Stock Analyst Ratings: Primoris Services Corp (NASDAQ:PRIM), BioCryst Pharmaceuticals, Inc. (NASDAQ ... - Review Fortune (NASDAQ:BCRX) - August 5 at 3:47 PM


BioCryst Pharmaceuticals (NASDAQ:BCRX) Chart for Friday, September, 30, 2016

Last Updated on 9/30/2016 by Staff